Showing results (51-60 of 142) with videos related to

Sort By:
Pageof 15
Plos One|December 6, 2011
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's diseaseMichal Mielcarek, Caroline L Benn, Sophie A Franklin, et al.
Journal of Proteome Research|March 4, 2006
Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopyTsz M Tsang, Ben Woodman, Gerard A McLoughlin, et al.
Nature Genetics|January 18, 2005
Polyglutamine expansion of huntingtin impairs its nuclear exportJonathan Cornett, Fengli Cao, Chuan-En Wang, et al.
Scientific Reports|November 8, 2019
Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's diseaseElaine E Irvine, Loukia Katsouri, Florian Plattner, et al.
Brain Communications|February 19, 2024
Translatable plasma and CSF biomarkers for use in mouse models of Huntington's diseaseMarie K Bondulich, Jemima Phillips, María Cañibano-Pico, et al.
Brain Research Bulletin|March 14, 2007
The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypesBen Woodman, Rachel Butler, Christian Landles, et al.
Annals of Neurology|August 2, 2003
Minocycline and doxycycline are not beneficial in a model of Huntington's diseaseDonna L Smith, Benjamin Woodman, Amarbirpal Mahal, et al.
Scientific Reports|May 4, 2017
The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patientsAndreas Neueder, Christian Landles, Rhia Ghosh, et al.
The European Journal of Neuroscience|September 30, 2005
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's diseaseEugenia Papalexi, Anna Persson, Maria Björkqvist, et al.
Pageof 15